Physician profile
Denice N Smith
NPI 1134171085
$1,495.72
in general payments reported to CMS, 2019-2025
24 companies · $274 in 2025
The $274 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $356 · 2020: $185 · 2021: $200 · 2022: $191 · 2023: $209 · 2024: $80.54 · 2025: $274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $564.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $563.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $351.69 | 2019-2020 | |
| Abbvie INC. | $302.17 | 2021-2023 | Ubrelvy, Qulipta |
| Alkermes, INC. | $144.15 | 2019-2025 | Lybalvi, Vivitrol |
| Axsome Therapeutics, INC. | $86.54 | 2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $77.88 | 2020-2025 | Invega Sustenna, Invega Trinza |
| Organon LLC | $76.41 | 2022-2025 | Nexplanon |
| Orexo US, INC. | $69.44 | 2021-2024 | Zubsolv |
| Dexcom, INC. | $50.02 | 2021-2023 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $37.97 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $37.27 | 2025 | Abilify Asimtufii, Abilify Maintena |
| Braeburn INC. | $35.98 | 2024-2025 | Brixadi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $34.11 | 2025 | Caplyta |
| Emd Serono, INC. | $22.28 | 2019 | |
| Merck Sharp & Dohme LLC | $18.91 | 2021 | |
| Nestle Healthcare Nutrition INC. | $18.78 | 2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Uswm, LLC | $17.03 | 2021 | |
| Sunovion Pharmaceuticals INC. | $17.02 | 2019 | |
| Hologic Sales and Service, LLC | $16.41 | 2024 | Aptima |
| Aimmune Therapeutics, INC. | $15.84 | 2025 | Zenpep |
| Exeltis, USA INC. | $14.23 | 2025 | Slynd |
| Exact Sciences Corporation | $14.23 | 2025 | The Cologuard Plus Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $14.03 | 2019 | |
| Novartis Pharmaceuticals Corporation | $11.76 | 2019 | |
| Pfizer INC. | $11.57 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Denice Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.